Chadi welcomes “Papa Heme,” or Aaron Goodman (@AaronGoodman33), MD, hematologist at University of California San Diego, and Matt Wilson (@mattwilson2287), MD, Beatson West of Scotland Cancer Centre (UK), to debate the importance and utility of CNS prophylaxis for patients with DLBCL. The trio explain the origins of the debate, who the high-risk patients are in the first place, whether better systemic control is a better strategy for these patients, how to weigh the benefits against the toxicities and other negative effects, and so much more. You don’t want to miss this informative and at times contentious dialogue.
